Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2024 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
April 08, 2024 08:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Provides Regulatory Update for SPN-830

ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
March 06, 2024 16:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in Two Upcoming Investor Conferences

ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
February 28, 2024 16:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference

ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
February 27, 2024 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces Fourth Quarter and Full Year 2023 Financial Results

Fourth quarter 2023 net sales of Qelbree® increased 97% to $46.4 million compared to fourth quarter 2022; Full year 2023 net sales of Qelbree increased 129% to $140.2 million compared to full year...
February 13, 2024 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024

ROCKVILLE, Md., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
February 05, 2024 08:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent

ROCKVILLE, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
November 08, 2023 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces Third Quarter 2023 Financial Results

Raises full year 2023 adjusted operating earnings (non-GAAP)(1) guidance range to $95 million to $110 million from previous range of $75 million to $100 millionTotal revenues (GAAP) of $153.9 million...
November 07, 2023 16:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in the Jefferies London Healthcare Conference

ROCKVILLE, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
November 02, 2023 07:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

ROCKVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...